<DOC>
	<DOC>NCT01618058</DOC>
	<brief_summary>The purpose of this trial is to determine if exposure to ARV-containing investigational products in IPM clinical trials will impact the natural history of HIV infection as measured by the virologic, immunologic and clinical outcomes of participants who become HIV-positive during the IPM 027 trial.</brief_summary>
	<brief_title>Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Recent HIV seroconversion during participation in IPM 027, according to the HIV testing algorithm of that trial Ability and willingness to provide informed consent Willingness to give the research centre permission to share information with the primary health care provider (PHCP), and willingness to sign approved sitespecific documentation to facilitate such sharing. Any condition that, in the opinion of the Investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>HIV-1</keyword>
</DOC>